Login to Your Account



Chi-Med advancing fruquintinib into phase III trial in gastric cancer

By Pearl Liu
Staff Writer

Wednesday, November 8, 2017

HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) said the phase III trial of its oral vascular endothelial growth factor (VEGF) inhibitor fruquintinib has begun. Named FRUTIGA, the randomized, double-blind, placebo-controlled, multicenter study is to test fruquintinib's efficacy and safety in combination with chemotherapy paclitaxel for the treatment of advanced gastric cancer, or gastroesophageal junction adenocarcinoma, in China.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription